Among the CYB5R genetic variants, CYB5R3 is well-characterized and deficiency in expression and activity is associated with type II methemoglobinemia, cancer, neurodegenerative disorders, diabetes, and cardiovascular disease. Here, CYB5R3 is linked to methemoglobinemia due to deficiency of methemoglobin reductase.